



February 27, 2025 – Updated Attachment A

Dear 340B Covered Entity,

Effective immediately, AbbVie is updating its 340B program integrity initiative to include Elahere[®] and Vyalev[®] in the list of AbbVie products subject to restriction. This change applies to both hospital and grantee covered entity types.

AbbVie's 340B program integrity initiative is designed to address persistent abuse of the 340B program, including diversion and inappropriate duplicate discounting. AbbVie's initiative does *not* block access to 340B priced medicines for any eligible covered entity and patients will continue to have uninterrupted access to AbbVie's medicines.

Under the initiative, AbbVie will decline to facilitate bill to/ ship to orders for all covered entity types for 340B-priced medicines. This limitation on bill to/ ship to orders is aligned with AbbVie's standard commercial sales conditions for non-340B customers. Accordingly, covered entities are not permitted to direct orders of AbbVie's 340B priced medicines to contract pharmacies, unless so provided under the limited conditions of this policy.

What is new under AbbVie's integrity initiative? Effective February 27, 2025, Elahere and Vyalev are being added to the list of applicable products included under this program integrity initiative. In addition, AbbVie has updated the FAQ section of our initiative. Please review the attached updated FAQ, which we hope you find easy to understand and apply.

Patients will continue to have uninterrupted access to AbbVie medicines, including Vyalev and Elahere. All covered entities are able to purchase 340B priced medicines for delivery to locations properly registered as a 340B covered entity or child site on the HRSA database to be dispensed from those sites.

What is AbbVie's policy for grantee covered entities? "Grantee" covered entity types listed in 42 U.S.C. §256(b)(4)(A)-(K) that wish to utilize contract pharmacies must register with 340B ESP[™], a web-based platform made available to covered entities at no cost, and submit requested claims data. AbbVie will use this claims data to identify ineligible or duplicate discounts. Grantee covered entities that elect not to register or provide the required claims data for a contract pharmacy will not be able to place bill to/ ship to orders of 340B priced drugs. Grantee covered entities that register and provide data will be able to use an unlimited number of contract pharmacies. Please refer to the Next Steps on page 3 and Frequently Asked Questions for Grantee Covered Entities on page 8 below.

What is AbbVie's policy for hospital covered entities? Except for the limited exceptions described below or in the attached FAQs, hospital covered entities may not place bill to/ ship to orders of 340B priced medicines for contract pharmacies.

A hospital covered entity *without* an in-house outpatient pharmacy may designate a single contract pharmacy location. AbbVie will facilitate bill to/ ship to orders of 340B priced medicines to that location only; provided that, (i) the covered entity submits limited claims data



on 340B utilization for such contract pharmacy location and (ii) the one contract pharmacy is located within 40 miles of the HRSA registered covered entity parent site. AbbVie is committed to ensuring that each hospital covered entity has at least one pharmacy location where it can receive shipments of discounted AbbVie medicines. If a hospital covered entity is unable to identify an eligible contract pharmacy within 40 miles, AbbVie will work with the covered entity to identify a suitable alternative. Please refer to the Frequently Asked Questions for Hospital Covered Entities on page 4 below.

AbbVie is committed to the intended purpose of the 340B program. If the 340B program is to fulfill its important mission of improving access to medicines for uninsured and vulnerable patients, program integrity challenges must be addressed. We look forward to working collaboratively with you to further strengthen the 340B program.

Please reach out to 340Bcommunications@abbvie.com if you have questions about our updated policy. For assistance with using 340 ESP™, please contact support@340BESP.com.

Best regards,

A handwritten signature in black ink, appearing to read "Edward Scheidler", is positioned above the printed name.

Edward Scheidler
Head of 340B Center of Excellence



NEXT STEPS FOR COVERED ENTITIES

To get started with the 340B ESP™ platform, follow these three simple steps:

1. Go to www.340BESP.com to register your account. Upon initial registration you will be prompted with an onboarding tutorial that will walk you through the account set up process step by step. This process takes about 15 minutes.
2. Once your account is activated, you will be able to securely upload data to 340B ESP™. You will receive periodic notifications of pending data submissions and new contract pharmacy set up activities.
3. Login to 340B ESP™ and submit your 340B contract pharmacy claims data twice monthly. Once your account is set up, the claims upload process takes about 5 minutes.

In addition to the frequently asked questions below, you can visit www.340BESP.com/FAQs to learn more about 340B ESP™. For further help with the registration, account setup, and data submission process you can access a repository of webinars at www.340BESP.com/resources/webinars or call Second Sight Solutions at 888-398-5520. Any changes to AbbVie's policy will be available in the most up-to-date policy document on www.340BESP.com.



FREQUENTLY ASKED QUESTIONS FOR HOSPITAL COVERED ENTITIES

Except in certain limited instances, hospital covered entities are not eligible to place bill to/ ship to replenishment orders of 340B priced medicines for contract pharmacies.

A hospital covered entity *without* an in-house outpatient pharmacy may designate one contract pharmacy location. AbbVie will facilitate bill to/ ship to orders of 340B priced medicines to that location only; provided that: (i) the covered entity submits limited claims data on 340B utilization for such contract pharmacy location and (ii) the one contract pharmacy is located within 40 miles of the HRSA registered covered entity parent site. AbbVie is committed to ensuring that each hospital covered entity has at least one pharmacy location where it can receive shipments of discounted AbbVie medicines. If a hospital covered entity is unable to identify an eligible contract pharmacy within 40 miles, AbbVie will work with the covered entity to identify a suitable alternative.

Q: Which AbbVie medicines are subject to this updated contract pharmacy policy?

The policy applies to the list of products attached to this FAQ. AbbVie will announce any changes to the product list. Both the AbbVie policy and the up-to-date list of AbbVie products can be found on 340B ESP™ website, www.340BESP.com.

Q: Am I still able to designate a contract pharmacy location for AbbVie medicines subject to a limited distribution network if my covered entity in-house outpatient pharmacy is not in the limited distribution network?

Yes. If your hospital covered entity's in-house outpatient pharmacy is not within a limited distribution network for an AbbVie product, you may designate one of the specified contract pharmacy locations for receiving replenishment shipment of the product. AbbVie will facilitate bill to/ ship to orders to this designated pharmacy location. This contract pharmacy designation is available for Duopa, Elahere, Imbruvica, Venclexta, and Vyalev. Please access 340B ESP™ at www.340BESP.com and navigate to the Entity Profile tab to make your selection. **Even if you had previously selected a designated one contract pharmacy location for Duopa, Imbruvica, or Venclexta, your covered entity must still access 340B ESP™ and select one designated pharmacy location for Elahere or Vyalev (or both). Your designated pharmacy location for Elahere and/or Vyalev must be listed in 340B ESP™ by March 9, 2025 for the designation to take effect on March 18, 2025.** If you have questions about how to make this designation, please contact Second Sight Solutions at 888-398-5520 or support@340BESP.com.

Q: Does my hospital covered entity have an “in-house outpatient pharmacy”?

An “in-house outpatient pharmacy” is any type of pharmacy—including but not limited to specialty pharmacy, retail pharmacy, or central fill pharmacy, that (i) is 100% owned by your covered entity, (ii) is appropriately licensed or authorized by the applicable state, (iii) is capable of dispensing covered outpatient drugs; and (iv) is not listed as a contract pharmacy for your covered entity on OPAIS.

It does not include a pharmacy partially owned by your covered entity, a pharmacy owned by an entity other than your covered entity, including a parent or affiliated entity other than your covered entity. Merely listing a non-entity owned pharmacy (i.e., a contract pharmacy) as a ship to address on OPAIS does not confer entity-owned status on the pharmacy. AbbVie may require eligibility information, such as auditable records, to confirm 100% ownership by your covered entity.

For purposes of clarity, if your covered entity has an “in-house outpatient pharmacy” as explained above, the entity **may not** designate a contract pharmacy.

Q: What if my hospital covered entity does not have an in-house outpatient pharmacy at the location appropriately registered as a parent or child site on the 340B covered entity database?



If your hospital covered entity does not have an in-house outpatient pharmacy capable of dispensing covered outpatient drugs, your hospital covered entity may designate a single contract pharmacy location. AbbVie will facilitate bill to/ ship to replenishment orders of 340B priced drugs to that contract pharmacy; *provided that*:

- (i) your hospital covered entity registers with 340B ESP™ and completes the attestation;
- (ii) your hospital covered entity provides AbbVie with appropriate documentation subject to AbbVie's sole discretion to support that your covered entity does not have an in-house outpatient pharmacy capable of dispensing covered outpatient drugs;
- (iii) your hospital covered entity submits limited claims data on 340B utilization for such contract pharmacy (see below for more details), and
- (iv) the one contract pharmacy is located within 40 miles of the HRSA registered covered entity parent site.

Q: What if my in-house outpatient pharmacy is capable of purchasing and dispensing 340B priced drugs but is not used to dispense AbbVie drugs or my hospital covered entity prefers to utilize a contract pharmacy. Is my hospital covered entity eligible to designate a contract pharmacy?

No. If your hospital covered entity has an in-house outpatient pharmacy capable of purchasing at the 340B price and dispensing, the covered entity is not eligible to also designate a contract pharmacy.

Q: Can child sites also designate a single contract pharmacy?

No. A child site must utilize the parent hospital site's contract pharmacy designation. AbbVie considers all sites together as one covered entity, inclusive of the parent and child sites, listed on the HRSA database.

Q: How can my hospital covered entity identify pharmacy locations within 40 miles of my parent hospital?

340B ESP™ will maintain a list of pharmacies within a 40-mile radius of the parent hospital registered on the HRSA 340B OPAIS database.

Q: What if I am unable to identify an eligible pharmacy location for my designation? For example, what if there is no pharmacy location within 40 miles of my covered entity's parent site?

AbbVie is committed to ensuring that every covered entity has at least one pharmacy location where it can receive AbbVie's medicines at 340B prices. If you are unable to locate a pharmacy location within 40 miles, AbbVie will work with your covered entity to locate the nearest appropriate contract pharmacy location. Please reach out to 340 ESP™ if you encounter challenges in designating your one contract pharmacy location.

Q: If my hospital covered entity is eligible to designate a contract pharmacy location because it does not have an in-house outpatient pharmacy, how does my hospital entity make its designation?

Hospital covered entities that are eligible to designate a single contract pharmacy can do so by registering an account at www.340BESP.com and navigating to the Entity Profile tab. The 340B ESP™ platform is the only way a covered entity can designate its single contract pharmacy location under AbbVie's policy.

Once during each 12-month period following the effective date of this policy, a covered entity may designate a different contract pharmacy location. Please note that such designations may take up to 10 business days to become effective.

Please note that designating a contract pharmacy does not in any way eliminate the program eligibility requirements and provide access to pricing to entities or individuals that do not meet the terms of this initiative. Hospital covered entities are responsible for ensuring that their particular contracting arrangements and operations conform to the requirements of all applicable laws and regulations.

Q: Does my covered entity need to have a HIN registered for the contract pharmacy that they designate?



Yes, a contract pharmacy must have a HIN assigned to it in order for a covered entity to designate it as its single contract pharmacy. This information is important for AbbVie to manage its process with its wholesalers. If you try to designate a contract pharmacy location that does not have a HIN in 340B ESP™, the system will provide guidance on how the contract pharmacy can be assigned a HIN. If you have previously registered a contract pharmacy without a HIN, 340B ESP™ will notify you if such information needs to be updated. If you have questions, please reach out to support@340BESP.com.

Q: If I designate one contract pharmacy location to receive orders of medicines subject to this policy, may I also make a separate designation for a contract pharmacy location to receive AbbVie medicines subject to a limited distribution network?

Yes, you may separately designate one contract pharmacy location to receive medicines subject to a limited distribution network. AbbVie will facilitate bill to/ ship to orders to this designated pharmacy. Currently, this separate contract pharmacy designation is available for Duopa, Elahere, Imbruvica, Venclexta, and Vyalev. Accordingly, this pharmacy designation may be in addition to the one permitted contract pharmacy designation for other AbbVie medicines. Please access 340B ESP™ at www.340BESP.com to make this selection.

Q: My hospital covered entity is affiliated with an outpatient pharmacy that is registered with HRSA as a contract pharmacy. How will AbbVie's policy impact this pharmacy location?

AbbVie will decline to facilitate bill to/ ship to orders for all contract pharmacies of hospital covered entities other than those identified in this policy. Your covered entity should place orders for delivery to your covered entity's in-house outpatient pharmacy. Hospital covered entities that do not have an in-house outpatient pharmacy may choose to designate an affiliated contract pharmacy as its sole designated contract pharmacy location, provided it complies with the data submission and distance requirements described herein.

Q: What are the requirements for submission of claims data for hospital covered entities?

The claims data submission requirement applies to hospital covered entities without an in-house outpatient pharmacy that designate one contract pharmacy location within 40 miles of the HRSA registered covered entity parent site. All specified claims data must be submitted within 45 days of the date of dispense to your covered entity's patient. Please submit claims data within the specified time period to ensure your designated contract pharmacy location remains eligible to receive 340B priced medicines. If purchases for the designated contract pharmacy location exceed conforming claims submitted according to this policy, this may result in the designated contract pharmacy losing eligibility to receive 340B priced medicines.

The 340B ESP™ platform requires claims uploads on the 1st and 16th of every month. Email reminders are automatically generated from 340B ESP™ and covered entities can monitor claims submission status when logged in to the platform. Please see 340B ESP™ at www.340BESP.com for additional details on submitting claims data, including the limited set of required data fields.

Q: How will AbbVie use the 340B claims data that covered entities provide through 340B ESP™?

Contract pharmacy claims data uploaded by 340B covered entities will be used to identify and resolve certain ineligible rebates (including in Medicaid, Medicare Part D, TRICARE, commercial payer rebates, and multiple 340B rebate requests on a single dispense), determine compliance with AbbVie's 340B integrity initiative, and determine eligibility for placing certain 340B orders under the policy. Only one covered entity may claim the 340B discount on each 340B-eligible dispense.

Q: What happens if my hospital covered entity is unable to provide claims data in conformance with AbbVie's policy?

Failure to provide claims data in conformance with the requirements of this policy may result in the designated contract pharmacy losing eligibility to receive 340B priced medicines. If you encounter challenges in submitting conforming claims data, please reach out to 340B ESP™ with questions. Please also ensure that your covered



entity's contract pharmacy administrator is aware of these policy requirements and takes any appropriate steps to assist with the submission of claims data. Specified claims data must be submitted within 45 days of the date of dispense to the covered entity's patient.

Q: May a hospital covered entity designate a single contract pharmacy 'replenishment' location, include dispensing activity from several other non-designated contract pharmacy locations of the same organization, and then create replenishment orders based on all the dispensing activity to a single replenishment location?

No. Contract pharmacy designations are specific to a location registered individually on the HRSA database by name and location. All dispensing to eligible patients must occur at the properly designated contract pharmacy location(s), and 340B priced drugs will be shipped directly to that location either by AbbVie or an authorized distributor.

Q: May my hospital covered entity tally dispensing activity from non-designated contract pharmacy locations and/ or a non-eligible pharmacy locations and place subsequent orders to be shipped to a different, single designated contract pharmacy or covered entity in-house location?

No. Contract pharmacy designations are specific to a location registered individually on the HRSA database by name and physical location, and 340B dispensing activity must occur at this location in order for the location to receive 340B priced drugs. Covered entities may not resell or otherwise transfer 340B covered outpatient drugs to a person who is not a patient of the covered entity.

Q: What if two covered entities attempt to order a 340B priced drug to replace the same prescription number or unit dispensed?

Multiple 340B requests on a single prescription (same prescription ID number) or unit will not be allowed. AbbVie will honor the first 340B discount request received and deny all subsequent requests.

Q: May my hospital covered entity (or my contract pharmacy) accept delivery of 340B-priced AbbVie drugs and ship them to another entity?

No. Consistent with federal wholesaling and redistribution laws, and AbbVie's standard sales terms and conditions, medicines may be purchased solely for the use by the purchasing entity. This excludes selling, transferring, or otherwise distributing product to any person or entity for resale or other purposes.

Q: Is there a time limitation on when orders can be placed to my designated contract pharmacy?

If the contract pharmacy has submitted claims data within 45 days of the date of dispensation by the contract pharmacy, AbbVie will process the contract pharmacy's order request.

You can visit www.340BESP.com/FAQs to learn more about 340B ESP™. For further help with the registration, account setup, and data submission process you can access a repository of webinars at www.340BESP.com/resources/webinars or call Second Sight Solutions at 888-398-5520. Any changes to AbbVie's policy will be available in the most up-to-date policy document on www.340BESP.com.



FREQUENTLY ASKED QUESTIONS FOR GRANTEE COVERED ENTITIES

Q: Which AbbVie medicines are subject to this updated contract pharmacy policy?

The policy applies to the list of products attached to this FAQ. AbbVie will announce any changes to the product list. Both the AbbVie policy and the up-to-date list of AbbVie products can be found on 340B ESP™ www.340BESP.com.

Q: What if my grantee covered entity would like to utilize or continue to utilize contract pharmacy arrangements?

AbbVie's 340B integrity initiative will honor grantee covered entities' bill to/ ship to requests for an unlimited number of contract pharmacies, *provided that*:

- (i) your 340B grantee covered entity registers with 340B ESP™ and your account is activated; and
- (ii) your 340B grantee covered entity submits limited claims data by the required date on 340B utilization for each contract pharmacy utilized (see below for more details).

Q: May my grantee covered entity utilize a contract pharmacy that is more than 40 miles from my location?

Yes. Grantee contract pharmacies are not restricted to the 40-mile radius that is a condition for hospital covered entity contract pharmacies.

Q: Does my grantee covered entity need to have a HIN registered for each contract pharmacy it utilizes?

Yes, a contract pharmacy must have a HIN assigned to it for a grantee covered entity to utilize it as a contract pharmacy. This information is important for AbbVie to manage its process with its wholesalers. If you try to utilize a contract pharmacy location that does not have a HIN in 340B ESP™, the system will provide guidance on how the contract pharmacy can be assigned a HIN. If you have previously registered a contract pharmacy without a HIN, 340B ESP™ will notify you if such information needs to be updated. If you have questions, please reach out to support@340BESP.com.

Q: Is my grantee covered entity required to designate one contract pharmacy location for AbbVie medicines subject to a limited distribution network?

No. You may continue to use the contract pharmacy location(s) within the applicable limited distribution network for receiving shipment of the applicable product, subject to the terms of this policy, such as timely submission of specified claims data. The AbbVie medicines available through a limited distribution network: 1) Duopa; 2) Elahere; 3) Imbruvica; 4) Venclexta; and 5) Vyalev. If you have questions, please reach out to support@340BESP.com.

Q: What are the requirements for submission of claims data for grantee covered entities?

All specified claims data must be submitted within 45 days of the date of dispense to your covered entity's patient. Please submit claims data within the specified period to ensure your contract pharmacy locations remain eligible to receive 340B priced medicines. If purchases for a contract pharmacy location exceed conforming claims submitted according to this policy, this may result in that contract pharmacy losing eligibility to receive 340B priced medicines.

The 340B ESP™ platform requires claims uploads on the 1st and 16th of every month. Email reminders are automatically generated from 340B ESP™ and covered entities can monitor claims submission status when logged in to the platform. Please see 340B ESP™ at www.340BESP.com for additional details on submitting claims data, including the limited set of required data fields.

Q: What happens if a covered entity that is already registered on the platform misses a data submission date?



If you miss a data submission date, please submit your data as soon as you are able. If a covered entity is repeatedly unable to provide required data in a timely manner, AbbVie may no longer facilitate bill to/ ship to contract pharmacy replenishment orders on 340B claims.

Q: Is my grantee covered entity limited to utilizing a single contract pharmacy?

No, provided your grantee covered entity takes the reasonable step to register with 340B ESP™ and continuously submit limited claims data on your 340B contract pharmacy utilization, you will continue to be able to use bill to/ ship to arrangements for AbbVie products with an **unlimited** number of contract pharmacies.

Q: How will AbbVie use the 340B claims data that covered entities provide through 340B ESP™?

Contract pharmacy claims data uploaded by 340B covered entities will be used to identify and resolve certain ineligible rebates (including in Medicaid, Medicare Part D, TRICARE, commercial payer rebates, and multiple 340B rebate requests on a single dispense), determine compliance with AbbVie's 340B integrity initiative, and determine eligibility for placing certain replenishment orders under the policy. Only one covered entity may claim the 340B discount on each 340B-eligible dispense.

Q: How do I get my contract pharmacy set up to meet the new requirements?

We do not anticipate any action being necessary on the part of contract pharmacies as this policy requires grantee covered entities to submit data for its contract pharmacy utilization. Grantee covered entities must register with the <http://www.340BESP.com> website and follow instructions to begin submitting data.

Q: What happens if my grantee covered entity does not provide 340B contract pharmacy claims data by the required date? 340B grantees that elect not to provide 340B claims data will no longer be able to place bill to/ ship to 340B orders for AbbVie products dispensed through a contract pharmacy.

Q: What training and resources will be provided to grantee covered entities to help with this transition?

Detailed information about how to use the 340B ESP™ platform can be found at www.340BESP.com/FAQS or email support@340BESP.com. The 340B ESP™ website includes video tutorials and answers to frequently asked questions.

Q: Is AbbVie requiring data for in-house outpatient pharmacies that are registered with HRSA as a covered entity?

No. AbbVie is only requiring 340B grantee covered entities to provide 340B claims data on units dispensed by contract pharmacies. Grantee covered entities do not need to provide 340B claims data for prescriptions filled in their own in-house outpatient pharmacies.

Q: What happens if my grantee covered entity is unable to provide claims data in conformance with AbbVie's policy?

Failure to provide claims data in conformance with the requirements of this policy may result in your contract pharmacies losing eligibility to receive 340B priced medicines. If you encounter challenges in submitting conforming claims data, please reach out to 340B ESP™ with questions. Please also ensure that your covered entity's contract pharmacy administrator is aware of these policy requirements and takes any appropriate steps to assist with the submission of claims data. Specified claims data must be submitted within 45 days of the date of dispense to the covered entity's patient.

Q: May my grantee covered entity utilize a single contract pharmacy 'replenishment' location, include dispensing activity from several other contract pharmacy locations of the same organization, and then create replenishment orders based on all the dispensing activity to a single replenishment location?



No. A contract pharmacy is specific to the location registered individually on the HRSA database by name and location. All dispensing to eligible patients must occur at the properly designated contract pharmacy location(s), and 340B priced drugs will be shipped directly to that location either by AbbVie or an authorized distributor.

Q: May my grantee covered entity tally dispensing activity from contract pharmacy locations and/ or a non-eligible pharmacy locations and place subsequent orders to be shipped to a different, individual contract pharmacy or covered entity in-house or ship to location?

No. A contract pharmacy is specific to a location registered individually on the HRSA database by name and physical location, and 340B dispensing activity must occur at this location in order for the location to receive 340B priced drugs. Covered entities may not resell or otherwise transfer 340B covered outpatient drugs to a person who is not a patient of the covered entity.

Q: What if two covered entities attempt to order a 340B priced drug to replace the same prescription number or unit dispensed?

Multiple 340B requests on a single prescription (same prescription ID number) or unit will not be allowed. AbbVie will honor the first 340B discount request received and deny all subsequent requests.

Q: May my grantee covered entity (or my contract pharmacy) accept delivery of 340B-priced AbbVie drugs and ship them to another entity?

No. Consistent with federal wholesaling and redistribution laws, and AbbVie's standard sales terms and conditions, medicines may be purchased solely for the use by the purchasing entity. This excludes selling, transferring, or otherwise distributing product to any person or entity for resale or other purposes.

Q: Is there a time limitation on when orders can be placed to my registered contract pharmacy?

If the grantee covered entity has submitted claims data within 45 days of the date of dispensation by the contract pharmacy, AbbVie will process the contract pharmacy's order request.

You can visit www.340BESP.com/FAQs to learn more about 340B ESP™. For further help with the registration, account setup, and data submission process you can access a repository of webinars at www.340BESP.com/resources/webinars or call Second Sight Solutions at 888-398-5520. Any changes to AbbVie's policy will be available in the most up-to-date policy document on www.340BESP.com.

**Attachment A
State Policies**

Arkansas: AbbVie's 340B program integrity initiative does not apply to covered entities in Arkansas.

Maryland: Covered entities located in Maryland may access 340B pricing at an unlimited number of contract pharmacies by submitting limited claims data through the 340B ESP™ platform for each of the covered entity's contract pharmacy arrangements. Covered entities in Maryland must submit claims data within 45 days of the date of dispensation by the contract pharmacy.

Minnesota: AbbVie's 340B program integrity initiative does not apply to covered entities in Minnesota.

Mississippi: AbbVie's 340B program integrity initiative does not apply to covered entities in Mississippi.

Missouri: AbbVie's 340B program integrity initiative does not apply to covered entities in Missouri.

AbbVie 340B Program Integrity Initiative Applicable Products

PRODUCT
ACTONEL®
ACULAR®
ACULAR® LS
ACUVAIL®
ALPHAGAN® P
ANDROGEL®
ARMOUR® THYROID
ATELVIA®
AVYCAZ®
BENTYL®
BOTOX®
BYSTOLIC®
CANASA®
CARAFATE®
CELEXA®
COMBIGAN®
CONDYLOX®
CREON®
CRINONE®
DALVANCE®
DELZICOL®
DEPAKOTE®
DUOPA®
DURYSTA®
ELAHERE®
ESTRACE®
FETZIMA®
FML FORTE®
FML®
GENERESS® FE
GENGRAF®
HUMIRA®
IMBRUVICA®
INFED®
KALETRA®
K-TAB®
KYBELLA®
LASTACAFT®
LATISSE®
LEXAPRO®

PRODUCT
LINZESS®
LO LOESTRIN® FE
LUMIGAN®
LUPRON®
MAVYRET®
NAMENDA® / NAMENDA XR®
NAMZARIC®
NORVIR®
OCUFLOX®
ORIAHNN®
ORILISSA®
OXYTROL®
OZURDEX®
PRED FORTE®
PRED MILD®
PYLERA®
QULIPTA®
RAPAFLO®
RECTIV®
REFRESH®
RESTASIS®
RINVOQ®
SAPHRIS®
SAVELLA®
SKYRIZI®
SURVANTA®
SYNTHROID®
TAYTULLA®
TEFLARO®
TRICOR®
TRILIPIX®
UBRELVY®
ULTANE®
URSO FORTE® / URSO 250®
VENCLEXTA®
VIBERZI®
VIIBRYD®
VRAYLAR®
VUITY®
VYALEV®
ZEMPLAR®